A Phase II trial of BGB-A317 in combination with chemotherapy for the first-line treatment of Chinese patients with locally advanced or metastatic esophageal, gastric, or gastroesophageal junction carcinoma.
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Tislelizumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 18 Aug 2017 New trial record